( Abbott's everolimus-eluting bioabsorbab...)Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent,Health

Abbott's everolimus-eluting bioabsorbable stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, the bioabsorbable stent is designed to restore blood flow by propping the vessel open, providing support until the blood vessel heals. Unlike a metallic stent, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

"Based on these encouraging safety results, Abbott will continue to advance this technology by enrolling the next cohort of patients in the ABSORB study in Europe and New Zealand," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "The next phase of the ABSORB study will utilize a next-generation bioabsorbable everolimus-eluting stent that incorporates several advancements designed to improve strength and deliverability."

About the ABSORB Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety -- MACE and stent thrombosis (blood clot formation) rates -- at 30, 180 and 270 days, with an annual follow-up for up to five years, and successful deployment of the bioabsorbable drug-eluting stent. Other key endpoints of the study include follow-up measurements assessed by angiography, IVUS, and state- of-the-art imaging modalities at 180 days and two years, as well as a new noninvasive technique in a subset of patients at 18 months. The co-principal investigator of the study is John Ormiston, M.D., of Mercy Hospital in Auckland, New Zealand.

For images of Abbott's bioabsorbable stent and other information, please visit the company's online ACC newsroom at http://www.abbottvascular.com/ACCpresskit .

About Abbot
'"/>

Page: 1 2 3
Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis